Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of in Rabbit Lungs

English version České info

Tuberculosis (TB) treatment is hampered by the long duration of antibiotic therapy required to achieve cure. This indolent response has been partly attributed to the ability of subpopulations of less metabolically active Mycobacterium tuberculosis (Mtb) to withstand killing by current anti-TB drugs. We have used immune modulation with a phosphodiesterase-4 (PDE4) inhibitor, CC-3052, that reduces tumor necrosis factor alpha (TNF-α) production by increasing intracellular cAMP in macrophages, to examine the crosstalk between host and pathogen in rabbits with pulmonary TB during treatment with isoniazid (INH). Based on DNA microarray, changes in host gene expression during CC-3052 treatment of Mtb infected rabbits support a link between PDE4 inhibition and specific down-regulation of the innate immune response. The overall pattern of host gene expression in the lungs of infected rabbits treated with CC-3052, compared to untreated rabbits, was similar to that described in vitro in resting Mtb infected macrophages, suggesting suboptimal macrophage activation. These alterations in host immunity were associated with corresponding down-regulation of a number of Mtb genes that have been associated with a metabolic shift towards dormancy. Moreover, treatment with CC-3052 and INH resulted in reduced expression of those genes associated with the bacterial response to INH. Importantly, CC-3052 treatment of infected rabbits was associated with reduced ability of Mtb to withstand INH killing, shown by improved bacillary clearance, from the lungs of co-treated animals compared to rabbits treated with INH alone. The results of our study suggest that changes in Mtb gene expression, in response to changes in the host immune response, can alter the responsiveness of the bacteria to antimicrobial agents. These findings provide a basis for exploring the potential use of adjunctive immune modulation with PDE4 inhibitors to enhance the efficacy of existing anti-TB treatment.

Vyšlo v časopise: Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of in Rabbit Lungs. PLoS Pathog 7(9): e32767. doi:10.1371/journal.ppat.1002262
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002262

Souhrn

Zdroje

1. DyeCWilliamsBG 2010 The population dynamics and control of tuberculosis. Science 328 856 861

2. de ChastellierC 2009 The many niches and strategies used by pathogenic mycobacteria for survival within host macrophages. Immunobiology 214 526 542

3. SaundersBMBrittonWJ 2007 Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 85 103 111

4. CosmaCLShermanDRRamakrishnanL 2003 The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol 57 641 676

5. PietersJ 2008 Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3 399 407

6. JordaoLBleckCKMayorgaLGriffithsGAnesE 2008 On the killing of mycobacteria by macrophages. Cell Microbiol 10 529 548

7. PaigeCBishaiWR 2009 Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol 12 301 309

8. StokesRWWaddellSJ 2009 Adjusting to a new home: Mycobacterium tuberculosis gene expression in response to an intracellular lifestyle. Future Microbiol 4 1317 1335

9. SteinbergBEGrinsteinS 2008 Pathogen destruction versus intracellular survival: the role of lipids as phagosomal fate determinants. J Clin Invest 118 2002 2011

10. ChanJFlynnJ 2004 The immunological aspects of latency in tuberculosis. Clin Immunol 110 2 12

11. FlannaganRSCosioGGrinsteinS 2009 Antimicrobial mechanisms of phagocytes and bacterial evasion strategies. Nat Rev Microbiol 7 355 366

12. RohdeKHAbramovitchRBRussellDG 2007 Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2 352 364

13. SchnappingerDEhrtSVoskuilMILiuYManganJA 2003 Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 198 693 704

14. DuttaNKMehraSDidierPJRoyCJDoyleLA 2010 Genetic requirements for the survival of tubercle bacilli in primates. J Infect Dis 201 1743 1752

15. TailleuxLWaddellSJPelizzolaMMortellaroAWithersM 2008 Probing host pathogen cross-talk by transcriptional profiling of both Mycobacterium tuberculosis and infected human dendritic cells and macrophages. PLoS One 3 e1403

16. HampshireTSonejiSBaconJJamesBWHindsJ 2004 Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: a model for persistent organisms? Tuberculosis (Edinb) 84 228 238

17. FlynnJLChanJ 2001 Immunology of tuberculosis. Annu Rev Immunol 19 93 129

18. KoulAHergetTKleblBUllrichA 2004 Interplay between mycobacteria and host signalling pathways. Nat Rev Microbiol 2 189 202

19. SahiratmadjaEAlisjahbanaBde BoerTAdnanIMayaA 2007 Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 75 820 829

20. SalgameP 2005 Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol 17 374 380

21. MacMickingJD 2009 Recognizing macrophage activation and host defense. Cell Host Microbe 5 405 407

22. LiuPTModlinRL 2008 Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 20 371 376

23. EhrtSSchnappingerD 2009 Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol 11 1170 1178

24. QuesniauxVFJacobsMAllieNGrivennikovSNedospasovSA 2010 TNF in host resistance to tuberculosis infection. Curr Dir Autoimmun 11 157 179

25. LyLHMcMurrayDN 2009 The Yin-Yang of TNFalpha in the guinea pig model of tuberculosis. Indian J Exp Biol 47 432 439

26. BekkerLGFreemanSMurrayPJRyffelBKaplanG 2001 TNF-alpha controls intracellular mycobacterial growth by both inducible nitric oxide synthase-dependent and inducible nitric oxide synthase-independent pathways. J Immunol 166 6728 6734

27. HaoSBaltimoreD 2009 The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol 10 281 288

28. BothaTRyffelB 2003 Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 171 3110 3118

29. BekkerLGHaslettPMaartensGSteynLKaplanG 2000 Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 181 954 965

30. KastRE 2000 Tumor necrosis factor has positive and negative self regulatory feed back cycles centered around cAMP. Int J Immunopharmacol 22 1001 1006

31. ZidekZ 1999 Adenosine - cyclic AMP pathways and cytokine expression. Eur Cytokine Netw 10 319 328

32. EiglerASiegmundBEmmerichUBaumannKHHartmannG 1998 Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 63 101 107

33. SerezaniCHBallingerMNAronoffDMPeters-GoldenM 2008 Cyclic AMP: master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39 127 132

34. SounessJEGriffinMMaslenCEbsworthKScottLC 1996 Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol 118 649 658

35. SounessJEAldousDSargentC 2000 Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47 127 162

36. DereeJMartinsJOMelbostadHLoomisWHCoimbraR 2008 Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 63 321 328

37. LeeTWFedorakRN 2010 Tumor necrosis factor-alpha monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Gastroenterol Clin North Am 39 543 557

38. TaylorPC 2010 Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol 10 308 315

39. MurdacaGColomboBMPuppoF 2009 Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 22 557 565

40. SampaioEPSarnoENGalillyRCohnZAKaplanG 1991 Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173 699 703

41. MoreiraALSampaioEPZmuidzinasAFrindtPSmithKA 1993 Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177 1675 1680

42. TramontanaJMUtaipatUMolloyAAkarasewiPBurroughsM 1995 Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1 384 397

43. CorralLGKaplanG 1999 Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 58 Suppl 1 I107 113

44. MarriottJBMullerGStirlingDDalgleishAG 2001 Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 1 675 682

45. BartlettJBMichaelAClarkeIADredgeKNicholsonS 2004 Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90 955 961

46. MarriottJBWestbyMCooksonSGuckianMGoodbournS 1998 CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol 161 4236 4243

47. CorralLGHaslettPAMullerGWChenRWongLM 1999 Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 380 386

48. MarriottJBClarkeIADredgeKMullerGStirlingD 2002 Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130 75 84

49. KooMSMancaCYangGO'BrienPSungN 2011 Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One 6 e17091

50. SirgelFADonaldPROdhiamboJGithuiWUmapathyKC 2000 A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45 859 870

51. FoxWEllardGAMitchisonDA 1999 Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3 S231 279

52. MitchisonDA 2003 Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 167 1298 1299

53. WeinerMBurmanWVernonABenatorDPeloquinCA 2003 Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 167 1341 1347

54. BettsJCMcLarenALennonMGKellyFMLukeyPT 2003 Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis. Antimicrob Agents Chemother 47 2903 2913

55. BoshoffHIMyersTGCoppBRMcNeilMRWilsonMA 2004 The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 279 40174 40184

56. WilsonMDeRisiJKristensenHHImbodenPRaneS 1999 Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A 96 12833 12838

57. KarakousisPCWilliamsEPBishaiWR 2008 Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 61 323 331

58. JoAnneLFlynnLTIzzoAngeloKaplanGilla 2008 Experimental Animal Models of Tuberculosis. KGaA, Weinheim Wiley-VCH Verlag GmBH&Co 389 426

59. LeeBYJethwaneyDSchillingBClemensDLGibsonBW The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome. Mol Cell Proteomics 9 32 53

60. MaYLiuHTu-RappHThiesenHJIbrahimSM 2004 Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat Immunol 5 380 387

61. ViaLELinPLRaySMCarrilloJAllenSS 2008 Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76 2333 2340

62. ParkHDGuinnKMHarrellMILiaoRVoskuilMI 2003 Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 48 833 843

63. BartekILRutherfordRGruppoVMortonRAMorrisRP 2009 The DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis (Edinb) 89 310 316

64. HomolkaSNiemannSRussellDGRohdeKH 2010 Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog 6 e1000988

65. SohaskeyCDWayneLG 2003 Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J Bacteriol 185 7247 7256

66. HumpelAGebhardSCookGMBerneyM 2010 The SigF regulon in Mycobacterium smegmatis reveals roles in adaptation to stationary phase, heat, and oxidative stress. J Bacteriol 192 2491 2502

67. SchnappingerD Schoolnik GK, Ehrt S 2006 Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another. Microbes Infect 8 1132 1140

68. WaddellSJStablerRALaingKKremerLReynoldsRC 2004 The use of microarray analysis to determine the gene expression profiles of Mycobacterium tuberculosis in response to anti-bacterial compounds. Tuberculosis (Edinb) 84 263 274

69. KaplanGTsenovaL 2010 Pulmonary Tuberculosis in the Rabbit. Leong F.JDVDickT A color atlas of comparative pathology of pulmonary tuberculosis Singapore CRC Press 107 130

70. KarakousisPCYoshimatsuTLamichhaneGWoolwineSCNuermbergerEL 2004 Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med 200 647 657

71. JindaniAAberVREdwardsEAMitchisonDA 1980 The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 121 939 949

72. VilchezeCJacobsWRJr 2007 The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 61 35 50

73. RussellDG 2001 Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2 569 577

74. BeavoJAContiMHeaslipRJ 1994 Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46 399 405

75. ContiMBeavoJ 2007 Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76 481 511

76. ShepherdMCBaillieGSStirlingDIHouslayMD 2004 Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 142 339 351

77. AgarwalNLamichhaneGGuptaRNolanSBishaiWR 2009 Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature 460 98 102

78. TaskenKAandahlEM 2004 Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84 137 167

79. Bengis-GarberCGruenerN 1996 Protein kinase A downregulates the phosphorylation of p47 phox in human neutrophils: a possible pathway for inhibition of the respiratory burst. Cell Signal 8 291 296

80. KalamidasSAKuehnelMPPeyronPRybinVRauchS 2006 cAMP synthesis and degradation by phagosomes regulate actin assembly and fusion events: consequences for mycobacteria. J Cell Sci 119 3686 3694

81. LinPLPlessnerHLVoitenokNNFlynnJL 2007 Tumor necrosis factor and tuberculosis. J Investig Dermatol Symp Proc 12 22 25

82. AkiraSTakedaK 2004 Toll-like receptor signalling. Nat Rev Immunol 4 499 511

83. BonizziGKarinM 2004 The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 280 288

84. LyLHJeevanAMcMurrayDN 2009 Neutralization of TNFalpha alters inflammation in guinea pig tuberculous pleuritis. Microbes Infect 11 680 688

85. RobertsEAChuaJKyeiGBDereticV 2006 Higher order Rab programming in phagolysosome biogenesis. J Cell Biol 174 923 929

86. ThuongNTDunstanSJChauTTThorssonVSimmonsCP 2008 Identification of tuberculosis susceptibility genes with human macrophage gene expression profiles. PLoS Pathog 4 e1000229

87. VolpeECappelliGGrassiMMartinoASerafinoA 2006 Gene expression profiling of human macrophages at late time of infection with Mycobacterium tuberculosis. Immunology 118 449 460

88. ShuiWGilmoreSASheuLLiuJKeaslingJD 2009 Quantitative proteomic profiling of host-pathogen interactions: the macrophage response to Mycobacterium tuberculosis lipids. J Proteome Res 8 282 289

89. RohdeKYatesRMPurdyGERussellDG 2007 Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev 219 37 54

90. CappelliGVolpeEGrassiMLiseoBColizziV 2006 Profiling of Mycobacterium tuberculosis gene expression during human macrophage infection: upregulation of the alternative sigma factor G, a group of transcriptional regulators, and proteins with unknown function. Res Microbiol 157 445 455

91. DebCLeeCMDubeyVSDanielJAbomoelakB 2009 A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 4 e6077

92. KaplanGPostFAMoreiraALWainwrightHKreiswirthBN 2003 Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun 71 7099 7108

93. VoskuilMISchnappingerDViscontiKCHarrellMIDolganovGM 2003 Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198 705 713

94. SirakovaTDDubeyVSDebCDanielJKorotkovaTA 2006 Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology 152 2717 2725

95. ShilohMUManzanilloPCoxJS 2008 Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe 3 323 330

96. PrimmTPAndersenSJMizrahiVAvarbockDRubinH 2000 The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol 182 4889 4898

97. KlinkenbergLGLeeJHBishaiWRKarakousisPC 2011 The stringent response is required for full virulence of Mycobacterium tuberculosis in guinea pigs. J Infect Dis 202 1397 1404

98. RosenkrandsISlaydenRACrawfordJAagaardCBarryCE3rd 2002 Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol 184 3485 3491

99. ConversePJKarakousisPCKlinkenbergLGKesavanAKLyLH 2009 Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun 77 1230 1237

100. KesavanAKBrooksMTufarielloJChanJManabeYC 2009 Tuberculosis genes expressed during persistence and reactivation in the resistant rabbit model. Tuberculosis (Edinb) 89 17 21

101. SachdevaPMisraRTyagiAKSinghY 2009 The sigma factors of Mycobacterium tuberculosis: regulation of the regulators. FEBS J 277 605 626

102. RaoVFujiwaraNPorcelliSAGlickmanMS 2005 Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J Exp Med 201 535 543

103. RaoVGaoFChenBJacobsWRJrGlickmanMS 2006 Trans-cyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis -induced inflammation and virulence. J Clin Invest 116 1660 1667

104. LeistikowRLMortonRABartekILFrimpongIWagnerK 2009 The Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy. J Bacteriol 192 1662 1670

105. ChauhanSSharmaDSinghASuroliaATyagiJS 2011 Comprehensive insights into Mycobacterium tuberculosis DevR (DosR) regulon activation switch. Nucleic Acids Res. E-pub ahead of print doi:10.1093/nar/gkr37

106. Saint-JoanisBSouchonHWilmingMJohnssonKAlzariPM 1999 Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase/peroxidase, KatG, from Mycobacterium tuberculosis. Biochem J 338 Pt 3 753 760

107. ParikhSLXiaoGTongePJ 2000 Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39 7645 7650

108. WengenackNLJensenMPRusnakFSternMK 1999 Mycobacterium tuberculosis KatG is a peroxynitritase. Biochem Biophys Res Commun 256 485 487

109. TimminsGSDereticV 2006 Mechanisms of action of isoniazid. Mol Microbiol 62 1220 1227

110. FontanPAArisVAlvarezMEGhannySChengJ 2008 Mycobacterium tuberculosis sigma factor E regulon modulates the host inflammatory response. J Infect Dis 198 877 885

111. MorrisRPNguyenLGatfieldJViscontiKNguyenK 2005 Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 102 12200 12205

112. NguyenLThompsonCJ 2006 Foundations of antibiotic resistance in bacterial physiology: the mycobacterial paradigm. Trends Microbiol 14 304 312

113. AdamsKNTakakiKConnollyLEWiedenhoftHWingleeK 2011 Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145 39 53

114. GuptaAKKatochVMChauhanDSSharmaRSinghM 2011 Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs. Microb Drug Resist 16 21 28

115. VilchezeCBaughnADTufarielloJLeungLKuoM 2011 Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother 55 3889 98

116. FlynnJLGoldsteinMMChanJTrieboldKJPfefferK 1995 Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 561 572

117. ChakravartySDZhuGTsaiMCMohanVPMarinoS 2008 Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs. Infect Immun 76 916 926

118. BernsteinDMLaneyCMorrisEKLoftusEF 2005 False beliefs about fattening foods can have healthy consequences. Proc Natl Acad Sci U S A 102 13724 13731

119. LynchMJHillEVHouslayMD 2006 Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. Curr Top Dev Biol 75 225 259

120. PasipanodyaJGMillerTLVecinoMMunguiaGGarmonR 2007 Pulmonary impairment after tuberculosis. Chest 131 1817 1824

121. SaliuOYSoferCSteinDSSchwanderSKWallisRS 2006 Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 486 492

122. La MaestraLZaninoniAMarriottJBLazzarinADalgleishAG 2000 The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro. Clin Exp Immunol 119 123 129

123. GuckianMDransfieldIHayPDalgleishAG 2000 Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro. Clin Exp Immunol 121 472 479

124. SpinaD 2008 PDE4 inhibitors: current status. Br J Pharmacol 155 308 315

125. BartlettJBDredgeKDalgleishAG 2004 The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4 314 322

126. SchaferPHPartonAGandhiAKCaponeLAdamsM 2010 Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159 842 855

127. TsenovaLBergtoldAFreedmanVHYoungRAKaplanG 1999 Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A 96 5657 5662

128. TsenovaLSokolKFreedmanVHKaplanG 1998 A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 177 1563 1572

129. TalaatAMLyonsRHowardSTJohnstonSA 2004 The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A 101 4602 4607

130. SubbianSMehtaPKCirilloSLCirilloJD 2007 The Mycobacterium marinum mel2 locus displays similarity to bacterial bioluminescence systems and plays a role in defense against reactive oxygen and nitrogen species. BMC Microbiol 7 4